Analysts Expect Aimmune Therapeutics (AIMT) Stock to Rise 198%; Rated Strong Buy

 

Aimmune Therapeutics (AIMT) stock is down -36.6% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives AIMT stock a score of 32 out of a possible 100.

That score is chiefly influenced by a short-term technical score of 1. AIMT’s score also includes a long-term technical score of 16. The fundamental score for AIMT is 81. In addition to the average rating from Wall Street analysts, AIMT stock has a mean target price of $54.17. This means analysts expect the stock to climb 197.96% over the next 12 months.

Click Here to get the full Stock Score Report on Aimmune Therapeutics Inc (AIMT).

What’s Happening with AIMT Stock Today

Aimmune Therapeutics Inc (AIMT) stock is down -8.6% while the S&P 500 is higher by 0.04% as of 3:17 PM on Thursday, Jul 11. AIMT is down -$1.71 from the previous closing price of $19.89 on volume of 1,911,658 shares. Over the past year the S&P 500 has gained 7.18% while AIMT is down -36.63%. AIMT lost -$3.67 per share in the over the last 12 months.

Symbols: AIMT

You May Also Like